News

Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's ...
The Globe and Mail15h
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - The Globe and Mail
Several factors are driving this expansion, including rising cancer ... AstraZeneca PLC (NASDAQ: AZN). Grand View Research continued: “The increasing prevalence of life-threatening conditions and the ...
Bispecifics/Bite Market Anticipates Impressive Growth Trajectory During The Forecast Period (2025-2034) Across 7MM Due To Their Expansion Beyond Oncology Delveinsight
The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted canc ...